Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared a post on X:
“2 messages in my opinion from Alex (OS no stat sign with 47% of pts in crizo receiving ALK TKI at PD, and no data stratified for that) and Flaura2 (crossing of curves in NON-high risk patients):
- sequencing is possible (better with brain active TKIs)
- descalate is possible in low-risk.”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss
